Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Finished Goods (2022)

Amylyx Pharmaceuticals has reported Finished Goods over the past 1 years, most recently at $937000.0 for Q4 2022.

  • Quarterly results put Finished Goods at $937000.0 for Q4 2022, changed N/A from a year ago — trailing twelve months through Dec 2022 was $937000.0 (changed N/A YoY), and the annual figure for FY2022 was $937000.0, changed.
  • Finished Goods for Q4 2022 was $937000.0 at Amylyx Pharmaceuticals, up from $110000.0 in the prior quarter.
  • Over the last five years, Finished Goods for AMLX hit a ceiling of $937000.0 in Q4 2022 and a floor of $110000.0 in Q3 2022.